Trial Profile
BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms BrUOG 354
- 25 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 24 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 26 Jan 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.